Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

Verkoop
 Koop

VirBiotechnology live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Christine Voong 2025 Jan 15, 08:00

TikTok Views and TikTok Viewer Trends: Elon Musk’s Potential Acquisition of TikTok and Its Market Impact

Stocks Tech Shares
Gold price graph
Tommy Yap 2025 Jan 14, 16:00

Morning Note: PPI Pressures USD, Eyes on CPI for Fed's Next Move

Morning Note USD Forex Gold Fed
Ahmed Abushar 2025 Jan 14, 16:00

Bitcoin’s Recovery: Why Is Crypto Going Up Amid Market Jitters?

Cryptocurrencies ETFs CFD Trading
Frances Wang 2025 Jan 13, 16:00

Potential TikTok ban: Chinese RedNote tops US app store

Stocks
Frances Wang 2025 Jan 13, 16:00

Phio stock surged 330%: Phio reports 100% tumor clearance

Stocks
Frances Wang 2025 Jan 13, 16:00

Oil Price Today: Oil Hits Four-Month High Following US Sanctions on Russia

Commodities
Frances Wang 2025 Jan 13, 16:00

Forex Markets Today: Markets Prepare for US Inflation Data

Forex
Frances Wang 2025 Jan 13, 16:00

Shiba Inu Coin Price Prediction: could this meme coin go higher?

Cryptocurrencies

Info

Spread

0.08

Spread (%)

0.7882 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Woensdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

1666410112

Uitstaande aandelen

137720000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-3.42

Meer informatie over dit instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten
Trustpilot
Live Chat